This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma (HORIZON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06023589
Recruitment Status : Recruiting
First Posted : September 5, 2023
Last Update Posted : April 22, 2024
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

Condition or disease Intervention/treatment Phase
Asthma Biological: Tezepelumab Other: Placebo Phase 3

Detailed Description:

This is a phase-3 multicentre, double-blind, parallel-group placebo-controlled, randomised study.

The study will comprise of:

  1. Screening/Run-in period of 4 to 6 weeks,
  2. 52-week double-blind Treatment period,
  3. Post-treatment Follow-up period of 12 weeks.

Participants will be randomised 2:1 to receive either tezepelumab or placebo administered by (SC) Subcutaneous injections for 52 weeks (double-blind Treatment period).

There will then be a 12-week off-treatment Follow-up period for participants who do not continue in the optional open-label Active Treatment Extension period.

An optional open-label Active Treatment Extension will allow all eligible participants the opportunity to receive active treatment with tezepelumab. The Active Treatment Extension period of the study will start following the 52-week double-blind Treatment period and will consist of a 24-week open-label Treatment period prior to the 12-week post-treatment Follow-up period.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 372 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized in a 2:1 ratio to either tezepelumab or matching placebo both administered subcutaneously
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-Blind
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)
Actual Study Start Date : August 24, 2023
Estimated Primary Completion Date : April 23, 2027
Estimated Study Completion Date : December 31, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Tezepelumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Tezepelumab
Participants will be receiving tezepelumab subcutaneous injection
 Biological: Tezepelumab
Participants will be receiving subcutaneous injection of tezepelumab
Other Name: MEDI9929 and AMG157
Placebo Comparator: Placebo
Participants will be receiving placebo through a subcutaneous injection
 Other: Placebo
Participants will be receiving subcutaneous injection of matching placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Annualized asthma exacerbation rate (AAER) [ Time Frame: From Baseline to Week 52 ]
    To assess the effect of tezepelumab on severe asthma exacerbations in children 5 to < 12 years old with severe uncontrolled asthma compared with placebo.


Secondary Outcome Measures :
  1. Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1) percent predicted normal (PN) [ Time Frame: From Baseline to Week 52 ]
    To assess the effect of tezepelumab on pulmonary function (FEV1) in children with severe uncontrolled asthma compared with placebo. Pre-bronchodilator FEV1% PN will be determined by spirometry at the clinic visit.

  2. AAER associated with allergic asthma [ Time Frame: From Baseline to Week 52 ]
    AAER will be assessed in association with both allergic asthma (defined by a positive perennial allergen using serum specific IgE [FEIA]).

  3. Time to first severe asthma exacerbation [ Time Frame: From Baseline to Week 52 ]
    Time to first severe asthma exacerbation will be assessed.

  4. Proportion of participants with ≥ 1 severe asthma exacerbation [ Time Frame: From Baseline to Week 52 ]
    Proportion of participants with ≥ 1 severe asthma exacerbation will be assessed.

  5. AAER associated with ER visit or hospitalisation [ Time Frame: From Baseline to Week 52 ]
    AAER will be assessed in association with ER visits or hospitalisations.

  6. Cumulative asthma exacerbation days [ Time Frame: From Baseline to Week 52 ]
    The cumulative asthma exacerbation days from baseline to week 52 will be assessed

  7. Change from baseline in Paediatric Asthma Quality of Life Questionnaire (PAQLQ-IA) total score [ Time Frame: From Baseline to Week 52 ]
    Change from baseline of PAQLQ-IA total score will be assessed. The PAQLQ was developed to measure the functional problems (physical, emotional, and social) that are most troublesome to children with asthma. The PAQLQ-IA has 23 questions in 3 domains (symptoms, activity limitation, and emotional function). Participants are asked to think about how they have been during the previous week and respond to each question on a 7-point scale (1 = extremely bothered to 7 = not bothered at all or 1 = all of the time to 7 = none of the time). There are 2 coloured cards (green and blue), which list sets of response options appropriate to different questions. The appropriate card should be used by the participant during completion of each question and then taken back when it is no longer required. The overall PAQLQ-IA score is the mean of all 23 responses and the individual domain scores are the means of the items in those domains.

  8. Change from baseline in weekly mean daily Paediatric Asthma Symptom Observer (PASO) score [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in PASO score will be assessed. The PASO questionnaire will be completed by the caregiver each day from the evening of Treatment period. Caregivers in this study will complete 4 items from the morning assessment capturing night-time asthma symptoms, rescue medication use, night-time awakenings, and maintenance asthma medication use. The evening assessment will capture daytime asthma symptoms, rescue medication use, activity limitation and change in asthma.

  9. Change from baseline in Asthma Control Questionnaire - Interviewer Administered (ACQ-IA) score [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in ACQ-IA score will be assessed. The ACQ-IA will only be completed for participants ≥ 6 years old at Screening. The ACQ-IA is administered by trained individuals according to standardised instructions to help the child understand concepts like symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheezing) and use of SABA during the past week using a 7-point scale. The ACQ-IA score is calculated by taking the mean of the 6 equally weighted items and ranges from 0 (well controlled) to 6 (extremely poorly controlled). The estimated minimal clinically important difference is 0.5

  10. Change from baseline in weekly mean rescue medication use [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in weekly mean rescue medication use will be assessed.

  11. Change from baseline in weekly mean number of night-time awakenings [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in weekly mean number of night-time awakenings will be assessed.

  12. Change from baseline in blood eosinophil count [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in blood eosinophil count will be assessed.

  13. Change from baseline in fractional exhaled nitric oxide (FeNO) [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in FeNO will be assessed.

  14. Change from baseline in total serum IgE [ Time Frame: From Baseline to Week 52 ]
    Change from baseline in total serum IgE will be assessed.

  15. Change from baseline in pre-bronchodilator (pre-BD) peak expiratory flow (PEF) [ Time Frame: From Baseline to Week 52 ]
    The effect of tezepelumab on pulmonary function compared with placebo will be assessed using spirometry.

  16. Number of asthma--related healthcare resource utilization (HRU) [ Time Frame: From Baseline to Week 52 ]
    Mean number and type of Asthma specific HRU (eg, unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) will be assessed.

  17. Number of participant/caregiver health-related absences [ Time Frame: From Baseline to Week 52 ]
    Mean number of participant/caregiver health-related absences from work/school due to asthma will be assessed.

  18. Serum concentrations of tezepelumab [ Time Frame: At Baseline, Week 4, Week 24, and Week 52 ]
    To evaluate the pharmacokinetics of tezepelumab.

  19. Incidence of anti-drug antibodies (ADAs) [ Time Frame: At Baseline, and from time of first dose at Week 0 to end of study at week 64 ]
    To evaluate the immunogenicity of tezepelumab.

  20. Incidence of neutralising antibodies (nAbs) [ Time Frame: At Baseline, and from time of first dose at Week 0 to end of study at week 64 ]
    To evaluate the immunogenicity of tezepelumab.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent from (ICF) at least one parent/caregiver (as per local guidelines) and accompanying informed assent from the participant (where the participant is able to provide assent) prior to admission to the study.
  2. Participants must be 5 to < 12 years of age, at the time of signing the assent form (as applicable per local guidelines) and their caregivers signing the ICF and at Visit 3.
  3. Documented physician diagnosis of severe asthma for at least 6 months prior to Visit 1.
  4. Documented physician-prescribed treatment with a total daily dose of either medium or high dose, for at least 3 months with stable dose ≥ 1 month prior to Visit 1.
  5. Documented treatment with at least one additional maintenance asthma controller medication is required according to local guidelines and standard of care; (long-acting beta agonist, leukotriene receptor antagonist, long-acting muscarinic antagonist) for at least 3 months with stable dose ≥ 1 month prior to Visit 1.

  6. Evidence of asthma as documented by one of the following:

    1. Documented historical BD responsiveness of FEV1 ≥ 10% in the previous 12 months prior to Visit 1 OR
    2. Documented historical methacholine challenge result of ≤ 16 mg/mL in the previous 12 months prior to Visit 1 OR
    3. Post-BD (albuterol/salbutamol) responsiveness of FEV1 ≥ 10% during Screening (15 to 30 min after administration of 4 puffs of albuterol/salbutamol) at either Visit 1 or Visit 2.
  7. History of at least 2 severe asthma exacerbation events OR 1 severe asthma exacerbation event resulting in hospitalisation within 12 months prior to Visit 1.
  8. Pre-BD FEV-1 >50% and ≤ 95%PN OR FEV1/forced vital capacity (FVC) ratio ≤ 0.8 at either Visit 1 or Visit 2.

  9. Evidence of uncontrolled asthma, with at least 1 of the below criteria:

    1. ACQ-IA score ≥ 1.5 at least once during Screening/Run-in, including Visit 3 (prior to Randomisation) for participants ≥ 6 years old at Screening
    2. Use of reliever medication, other than as a preventive for exercise induced bronchospasm, on 3 or more days per week for at least 1 week during the Screening/Run-in period
    3. Sleep awakening due to asthma symptoms requiring use of reliever medication at least once during the Screening/Run-in period
    4. Asthma symptoms 3 or more days per week in at least 1 week during the Screening/Run-in period
  10. Body weight ≥ 16 kg at Visit 1 (Screening) and Visit 3 (Randomisation).

Exclusion Criteria:

  1. History of cystic fibrosis, primary ciliary dyskinesia, or chronic rhinosinusitis with nasal polyposis.
  2. History of any clinically significant disease or disorder other than asthma which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  3. History of a clinically significant deterioration in asthma or asthma exacerbation including those requiring use of systemic corticosteroids or increase in the maintenance dose of oral corticosteroids within 30 days prior to Visit 1.
  4. Change in ICS dose within 1 month prior to Visit 1.
  5. History of a life-threatening asthma exacerbation resulting in a hypoxic seizure or requiring intubation or mechanical ventilation.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06023589


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Show Show 97 study locations
Sponsors and Collaborators
AstraZeneca
Amgen
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT06023589    
Other Study ID Numbers: D5180C00016
First Posted: September 5, 2023    Key Record Dates
Last Update Posted: April 22, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Asthma
Uncontrolled Asthma
Severe Uncontrolled Asthma
Human monoclonal antibody (IgG2λ) cytokine
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases